Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on HitIQ.
RELATED STOCKHEAD STORIES
Tech
Four ASX stocks seeking a competitive edge in the lucrative sports market
Health & Biotech
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
Health & Biotech
ASX Health Stocks: Amplia’s pancreatic cancer drug shows progress
Health & Biotech
ASX Health Stocks: CBL targets more reimbursement revenue for NeuroNode device
Health & Biotech
ASX Health Stocks: HITIQ secures US patent; BlinkLab joins forces in Europe to transform ADHD diagnosis
Health & Biotech
ASX Health Stocks: HitIQ’s mouthguard approved by World Rugby; Neurotech reports positive results
Health & Biotech
The next Neuren? Nyrada chases after two big markets – stroke and traumatic brain injury
Health & Biotech
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Health & Biotech
Diagnosing mental disorder through sleep: How TrivarX could capture this huge research market
News
Rise and Shine: Everything you need to know before the ASX opens
News
Top 10 at 10: Minnow soars to 80pc gain on AFL deal
News
In Case You Missed It: High grade gold for the win
Experts
CRITERION: Do these ASX plays of the day deserve a sporting chance?
Experts
How to play the blockbuster UFC-WWE merger, and why these sports stocks could also be good investments
Health & Biotech
ASX Health Stocks: Neuren surges 20pc on ‘historic’ FDA approval, HITIQ snaps up Monash Uni as customer
News
Market Highlights: Defiant Wall Street, Man U for sale, and 5 ASX small caps to watch today
Health & Biotech
